Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Ka Tat Siu, PhD, Janani Ramachandran, MA, Andrew J. Yee, MD, Homare Eda, MD PhD, Loredana Santo, MD, Elizabeth K. O'Donnell, MD, Cristina Panaroni, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Michael Cooper, MD, Noopur Raje, MD

Blood (2016) 128 (22): 3320.

https://doi.org/10.1182/blood.V128.22.3320.3320

Published: 2016

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Noopur S. Raje, MD

Blood (2011) 118 (21): 1819.

https://doi.org/10.1182/blood.V118.21.1819.1819

Published: 2011

Journal Articles

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Diana Cirstea, MD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Scott Rodig, MD, PhD, Miriam Canavese, PhD, James Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2908.

https://doi.org/10.1182/blood.V118.21.2908.2908

Published: 2011

Journal Articles

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Walter C Ogier, Diana D. Cirstea, MD, Scott Rodig, MD, PhD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Miriam Canavese, PhD, James E. Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2912.

https://doi.org/10.1182/blood.V118.21.2912.2912

Published: 2011

Journal Articles

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Diana Cirstea, MD, Teru Hideshima, MD, PhD, Loredana Santo, MD, Homare Eda, MD, PhD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Anuj K. Mahindra, MD, Gullu Gorgun, PhD, Yiguo Hu, MD, PhD, Naoya Mimura, MD, PhD, Claire Fabre, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Kenneth C. Anderson, MD, Sylvie M Guichard, PharmD, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2916.

https://doi.org/10.1182/blood.V118.21.2916.2916

Published: 2011

Journal Articles

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Erica Evans, PhD, Juswinder Singh, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2882.

https://doi.org/10.1182/blood.V118.21.2882.2882

Published: 2011

Journal Articles

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

Samantha Pozzi, MD, Diana Cirstea, M.D., Loredana Santo, MD, Doris M Nabikejje, Kishan Patel, Kathryn M Luly, Gaurav Gharti-Chhetry, Sonia Vallet, MD, Homare Eda, MD, PhD, Teru Hideshima, MD, Simon R Green, Kenneth C. Anderson, MD, David T. Scadden, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2999.

https://doi.org/10.1182/blood.V116.21.2999.2999

Published: 2010

NARROW

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

Email alerts

ASH Publications

American Society of Hematology

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only